Cargando…

Geraniol Treatment for Irritable Bowel Syndrome: A Double-Blind Randomized Clinical Trial

Geraniol is an acyclic monoterpene alcohol with well-known anti-inflammatory and antimicrobial properties which has shown eubiotic activity towards gut microbiota (GM) in patients with irritable bowel syndrome (IBS). Methods: Fifty-six IBS patients diagnosed according to Rome III criteria were enrol...

Descripción completa

Detalles Bibliográficos
Autores principales: Ricci, Chiara, Rizzello, Fernando, Valerii, Maria Chiara, Spisni, Enzo, Gionchetti, Paolo, Turroni, Silvia, Candela, Marco, D’Amico, Federica, Spigarelli, Renato, Bellocchio, Irene, Marasco, Giovanni, Barbara, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9571173/
https://www.ncbi.nlm.nih.gov/pubmed/36235860
http://dx.doi.org/10.3390/nu14194208
_version_ 1784810296277204992
author Ricci, Chiara
Rizzello, Fernando
Valerii, Maria Chiara
Spisni, Enzo
Gionchetti, Paolo
Turroni, Silvia
Candela, Marco
D’Amico, Federica
Spigarelli, Renato
Bellocchio, Irene
Marasco, Giovanni
Barbara, Giovanni
author_facet Ricci, Chiara
Rizzello, Fernando
Valerii, Maria Chiara
Spisni, Enzo
Gionchetti, Paolo
Turroni, Silvia
Candela, Marco
D’Amico, Federica
Spigarelli, Renato
Bellocchio, Irene
Marasco, Giovanni
Barbara, Giovanni
author_sort Ricci, Chiara
collection PubMed
description Geraniol is an acyclic monoterpene alcohol with well-known anti-inflammatory and antimicrobial properties which has shown eubiotic activity towards gut microbiota (GM) in patients with irritable bowel syndrome (IBS). Methods: Fifty-six IBS patients diagnosed according to Rome III criteria were enrolled in an interventional, prospective, multicentric, randomized, double-blinded, placebo-controlled trial. In the treatment arm, patients received a low-absorbable geraniol food supplement (LAGS) once daily for four weeks. Results: Patients treated with LAGS showed a significant reduction in their IBS symptoms severity score (IBS-SSS) compared to the placebo (195 vs. 265, p = 0.001). The rate of responders according to IBS-SSS (reduction ≥ 50 points) was significantly higher in the geraniol vs placebo group (52.0% vs. 16.7%, p = 0.009) mainly due to the IBS mixed subtype. There were notable differences in the microbiota composition after geraniol administration, particularly a significant decrease in a genus of Ruminococcaceae, Oscillospira (p = 0.01), a decreasing trend for the Erysipelotrichaceae and Clostridiaceae families (p = 0.1), and an increasing trend for other Ruminococcaceae taxa, specifically Faecalibacterium (p = 0.09). The main circulating proinflammatory cytokines showed no differences between placebo and geraniol arms. Conclusion: LAGS was effective in treating overall IBS symptoms, together with an improvement in the gut microbiota profile, especially for the IBS mixed subtype.
format Online
Article
Text
id pubmed-9571173
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95711732022-10-17 Geraniol Treatment for Irritable Bowel Syndrome: A Double-Blind Randomized Clinical Trial Ricci, Chiara Rizzello, Fernando Valerii, Maria Chiara Spisni, Enzo Gionchetti, Paolo Turroni, Silvia Candela, Marco D’Amico, Federica Spigarelli, Renato Bellocchio, Irene Marasco, Giovanni Barbara, Giovanni Nutrients Article Geraniol is an acyclic monoterpene alcohol with well-known anti-inflammatory and antimicrobial properties which has shown eubiotic activity towards gut microbiota (GM) in patients with irritable bowel syndrome (IBS). Methods: Fifty-six IBS patients diagnosed according to Rome III criteria were enrolled in an interventional, prospective, multicentric, randomized, double-blinded, placebo-controlled trial. In the treatment arm, patients received a low-absorbable geraniol food supplement (LAGS) once daily for four weeks. Results: Patients treated with LAGS showed a significant reduction in their IBS symptoms severity score (IBS-SSS) compared to the placebo (195 vs. 265, p = 0.001). The rate of responders according to IBS-SSS (reduction ≥ 50 points) was significantly higher in the geraniol vs placebo group (52.0% vs. 16.7%, p = 0.009) mainly due to the IBS mixed subtype. There were notable differences in the microbiota composition after geraniol administration, particularly a significant decrease in a genus of Ruminococcaceae, Oscillospira (p = 0.01), a decreasing trend for the Erysipelotrichaceae and Clostridiaceae families (p = 0.1), and an increasing trend for other Ruminococcaceae taxa, specifically Faecalibacterium (p = 0.09). The main circulating proinflammatory cytokines showed no differences between placebo and geraniol arms. Conclusion: LAGS was effective in treating overall IBS symptoms, together with an improvement in the gut microbiota profile, especially for the IBS mixed subtype. MDPI 2022-10-10 /pmc/articles/PMC9571173/ /pubmed/36235860 http://dx.doi.org/10.3390/nu14194208 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ricci, Chiara
Rizzello, Fernando
Valerii, Maria Chiara
Spisni, Enzo
Gionchetti, Paolo
Turroni, Silvia
Candela, Marco
D’Amico, Federica
Spigarelli, Renato
Bellocchio, Irene
Marasco, Giovanni
Barbara, Giovanni
Geraniol Treatment for Irritable Bowel Syndrome: A Double-Blind Randomized Clinical Trial
title Geraniol Treatment for Irritable Bowel Syndrome: A Double-Blind Randomized Clinical Trial
title_full Geraniol Treatment for Irritable Bowel Syndrome: A Double-Blind Randomized Clinical Trial
title_fullStr Geraniol Treatment for Irritable Bowel Syndrome: A Double-Blind Randomized Clinical Trial
title_full_unstemmed Geraniol Treatment for Irritable Bowel Syndrome: A Double-Blind Randomized Clinical Trial
title_short Geraniol Treatment for Irritable Bowel Syndrome: A Double-Blind Randomized Clinical Trial
title_sort geraniol treatment for irritable bowel syndrome: a double-blind randomized clinical trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9571173/
https://www.ncbi.nlm.nih.gov/pubmed/36235860
http://dx.doi.org/10.3390/nu14194208
work_keys_str_mv AT riccichiara geranioltreatmentforirritablebowelsyndromeadoubleblindrandomizedclinicaltrial
AT rizzellofernando geranioltreatmentforirritablebowelsyndromeadoubleblindrandomizedclinicaltrial
AT valeriimariachiara geranioltreatmentforirritablebowelsyndromeadoubleblindrandomizedclinicaltrial
AT spisnienzo geranioltreatmentforirritablebowelsyndromeadoubleblindrandomizedclinicaltrial
AT gionchettipaolo geranioltreatmentforirritablebowelsyndromeadoubleblindrandomizedclinicaltrial
AT turronisilvia geranioltreatmentforirritablebowelsyndromeadoubleblindrandomizedclinicaltrial
AT candelamarco geranioltreatmentforirritablebowelsyndromeadoubleblindrandomizedclinicaltrial
AT damicofederica geranioltreatmentforirritablebowelsyndromeadoubleblindrandomizedclinicaltrial
AT spigarellirenato geranioltreatmentforirritablebowelsyndromeadoubleblindrandomizedclinicaltrial
AT bellocchioirene geranioltreatmentforirritablebowelsyndromeadoubleblindrandomizedclinicaltrial
AT marascogiovanni geranioltreatmentforirritablebowelsyndromeadoubleblindrandomizedclinicaltrial
AT barbaragiovanni geranioltreatmentforirritablebowelsyndromeadoubleblindrandomizedclinicaltrial